BBC-incubated startup Stabicon uses curcumin & turmerones to mitigate COVID-19


Based on the Zuicel™ technology, a product called CD4 shield is developed by Vijay Kumar Ranka & his team

One of the startup companies of Bangalore Bioinnoavtion Centre (BBC), Stabicon has been working on prevention programme for the novel coronavirus using the company’s proprietary Zuicel technology.

It consists of holistic turmeric active concentrate of curcumin & turmerones with high efficacy under very significant low dose of 1 – 10mg for health & wellness segment. The programme is based on regenerative medicine properties and has massive potential for treating pre-metabolic & metabolic syndrome from last 8 years.

During a controlled clinical trial for metabolic syndrome evaluation, the outcome has concluded to be safe & therapeutic. The data is supported by pool of global scientific publication evidence that solubility improved by Zuicel technology on Curcumin & turmerones.

The observation was, the technology assists on molecular action in modulating immune system against host specific attack as well as breaking down coronavirus machinery process. This observation led to repurposing of existing innovative solution towards preventive and curative care programme against coronavirus outbreak.

Based on the Zuicel™ technology, a product called CD4 shield developed by Vijay Kumar Ranka & his team was launched by Dr AshwathNarayan C N, Deputy Chief Minister and Minister of Electronics, IT, BT and S&T, Government of Karnataka in presence of Dr. Krishnaswamy VijayRaghavan, Principal scientific adviser, Government of India.

The use of Zuicel™ technology on curcumin and turmerones along with cyanocobalamin has improved bioavailability due to Hydrophilic – lipophilic mechanism allow it to reaches to target site for activation via microvilli into systemic pathway. 

Read Previous

Indus Best Mega Food Park opens at Raipur

Read Next

Max Protein launches first-ever protein peanut butter in 5 flavours

Leave a Reply